FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency

Area of Science:

• Metabolic diseases
• Endocrinology
• Cellular biology

Background:

• Berardinelli-Seip congenital lipodystrophy (BSCL) is linked to seipin deficiency, causing adipose tissue loss and metabolic dysfunction.
• Fibroblast growth factor 21 (FGF21) is known to improve metabolic homeostasis.
• The role of FGF21 in BSCL-related adipocyte dysfunction requires further investigation.

Purpose of the Study:

• To investigate the therapeutic potential of FGF21 in a mouse model of BSCL.
• To elucidate the molecular mechanisms underlying seipin deficiency-induced adipocyte dysfunction.
• To determine if FGF21 can mitigate adipocyte loss and improve metabolic parameters in BSCL.

Main Methods:

• Treatment of Bscl2^-/- mice with an FGF21 analog (LY2405319).
• Assessment of metabolic parameters, including insulin sensitivity and adiponectin levels.
• Development of a seipin knockdown cell line (SKD) to study adipocyte dysfunction in vitro.
• Analysis of the p38 MAPK pathway activation and its role in adipocyte apoptosis.

Main Results:

• FGF21 treatment normalized insulin sensitivity and increased adiponectin levels in Bscl2^-/- mice.
• Seipin deficiency in mature adipocytes led to chronic p38 MAPK activation and apoptotic cell death.
• FGF21 treatment reduced p38 MAPK phosphorylation and protected adipocytes from stress-induced loss.
• FGF21 improved the white adipose tissue gene expression pattern in treated mice.

Conclusions:

• FGF21 treatment ameliorates the metabolic profile of Bscl2^-/- lipodystrophic mice.
• FGF21 protects mature adipocytes by suppressing cellular stress through p38 MAPK pathway inhibition.
• FGF21 represents a potential therapeutic strategy for managing adipocyte dysfunction in BSCL.